Agilent Technologies stock reports 8.1 percent revenue growth

Agilent Technologies stock was trading at USD 166.30 on the NYSE on September 24, 2026 at 9:34 a.m. ET, while the company reported fiscal third-quarter revenue of USD 1.88 billion. The quarter ended July 31, 2026, and revenue increased 8.1 percent from the prior-year period, giving investors a fresh measure of demand across the laboratory technology group.

Revenue reaches USD 1.88 billion

Agilent reported USD 362 million in GAAP net income for fiscal Q3, equal to GAAP EPS of USD 1.28. Non-GAAP EPS reached USD 1.62, including a USD 0.06 benefit from tariff refunds, compared with USD 1.37 in the year-ago quarter.

The revenue result also exceeded the USD 1.84 billion analyst estimate, while adjusted EPS was above the USD 1.49 consensus by USD 0.13, according to Yahoo Finance. That comparison matters because the earnings beat was wider than the top-line difference, pointing to operating leverage alongside sales growth.

Guidance moves higher

Agilent raised its fiscal 2026 adjusted EPS guidance to USD 6.18 to USD 6.21, including the tariff-refund benefit. The midpoint of USD 6.195 stands above the prior consensus of USD 6.06, while full-year revenue guidance increased to USD 7.49 billion to USD 7.51 billion, as Investing.com reported on August 26, 2026.

The guidance upgrade gives the stock a measurable earnings reference after the July quarter. It also separates reported growth from the one-time tariff effect, since management presented an adjusted EPS range of USD 6.12 to USD 6.15 excluding that benefit.

Stock trades near yearly high

Agilent Technologies stock stood 1.56 percent below its 52-week high of USD 168.94 on September 24, 2026. Its 52-week low was USD 108.35, placing the intraday price 53.58 percent above that lower mark and giving the market reaction a clear historical frame.

The stock was trading at USD 166.30 on the NYSE on September 24, 2026. Agilent Technologies, Inc. operates in healthcare and medical diagnostics and research, with laboratory instruments, services and diagnostics products forming the core business.